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Abstract
Introduction: Discrepancies of 5-24% between superior vena cava oxygen saturation (ScvO2) and mixed venous
oxygen saturation (SvO2) have been reported in patients with severe heart failure. Thenar muscle tissue
oxygenation (StO2) measured with near-infrared spectroscopy (NIRS) during arterial occlusion testing decreases
slower in sepsis/septic shock patients (lower StO2 deoxygenation rate). The StO2 deoxygenation rate is influenced
by dobutamine. The aim of this study was to determine the relationship between the StO2 deoxygenation rate and
the ScvO2-SvO2 discrepancy in patients with severe left heart failure and additional sepsis/septic shock treated with
or without dobutamine.
Methods: Fifty-two patients with severe left heart failure due to primary heart disease with additional severe
sepsis/septic shock were included. SvO2 and ScvO2 were compared to the thenar muscle StO2 before and during
arterial occlusion.
Results: SvO2 correlated significantly with ScvO2 (Pearson correlation 0.659, P = 0.001), however, Bland Altman
analysis showed a clinically important difference between both variables (ScvO2-SvO2 mean 72 ± 8%, ScvO2-SvO2
difference 9.4 ± 7.5%). The ScvO2-SvO2 difference correlated with plasma lactate (Pearson correlation 0.400, P =
0.003) and the StO2 deoxygenation rate (Pearson correlation 0.651, P = 0.001). In the group of patients treated with
dobutamine, the ScvO2-SvO2 difference correlated with plasma lactate (Pearson correlation 0.389, P = 0.011) and
the StO2 deoxygenation rate (Pearson correlation 0.777, P = 0.0001).
Conclusions: In patients with severe heart failure with additional severe sepsis/septic shock the ScvO2-SvO2
discrepancy presents a clinical problem. In these patients the skeletal muscle StO2 deoxygenation rate is inversely
proportional to the difference between ScvO2 and SvO2; dobutamine does not influence this relationship. When
using ScvO2 as a treatment goal, the NIRS measurement may prove to be a useful non-invasive diagnostic test to
uncover patients with a normal ScvO2 but potentially an abnormally low SvO2.
Trial Registration: NCT00384644 ClinicalTrials.Gov.
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M a i n t e n a n c eo fa d e q u a t eo x y g e nd e l i v e r y( D O 2)i s
essential to preserve organ function, because a sustained
low DO2 leads to organ failure and death [1]. Low car-
diac output states (cardiogenic, hypovolemic and
obstructive types of shock), anemic and hypoxic hypoxe-
mia are characterized by a decreased DO2 but a pre-
served oxygen extraction ratio. In distributive shock, the
oxygen extraction capability is altered so that the critical
oxygen extraction ratio is typically decreased [2]. Mea-
surement of mixed venous oxygen saturation (SvO2)
from the pulmonary artery is used for calculations of
oxygen consumption and has been advocated as an
indirect index of tissue oxygenation and a prognostic
predictor in critically ill patients [3-6]. However, cathe-
terization of the pulmonary artery is costly, has inherent
risks and its usefulness remains under debate [7,8].
Not surprisingly the monitoring of central venous oxy-
g e ns a t u r a t i o n( S c v O 2) was suggested as a simpler and
cheaper assessment of global DO2 to oxygen consump-
tion ratio [1,2].
Ac o n c e r nw i t hS c v O 2 compared with mixed venous
oxygen saturation (SvO2) is that it may not accurately
reflect global hypoxia, because organs with capillary
beds that drain into the inferior vena cava or coronary
sinus will not be involved in this measurement. Healthy
resting individuals have a ScvO2 that is slightly lower
than the SvO2 [3]. In heart failure and shock, however,
this situation is reversed. Most authors attribute this
pattern to changes in the distribution of cardiac output
that occur in periods of haemodynamic instability. In
shock states, blood flow to the splanchnic and renal cir-
culations fall, while flow to the heart and brain is main-
tained due to redistribution of blood away from the
mesenteric and renal vascular beds and additional right
heart dysfunction [4]. Discrepancies of 5 to 24% have
been reported [5-7,9].
Near infrared spectroscopy (NIRS) is a technique used
for continuous, non-invasive, bedside monitoring of tis-
sue oxygen saturation (StO2) [8,10].
We have previously shown that skeletal muscle StO2
does not estimate SvO2 in patients with severe left
heart failure and additional severe sepsis or septic
shock. However, in patients with severe left heart fail-
ure without additional severe sepsis or septic shock,
StO2 values could be used for fast noninvasive SvO2
estimation; the trend of StO2 may be substituted for
the trend of SvO2 [8].
We have also shown that thenar skeletal muscle StO2
during stagnant ischemia (deoxygenation rate during
arterial occlusion test) decreases slower in septic shock
patients compared with patients with severe sepsis or
localized infection or healthy volunteers [10].
Impaired skeletal muscle microcirculation, especially
impaired deoxygenation rate during arterial occlusion
test, was recently detected in patients with chronic heart
failure. Dobutamine, but not levosimendan, partially
reversed this impairment [11].
The aim of current study was to combine our previous
findings. We tested the hypothesis that in patients with
severe left heart failure and additional sepsis/septic
shock the skeletal muscle deoxygenation rate during an
arterial occlusion test could predict a ScvO2-SvO2 dis-
crepancy. The second aim was to explore the effect of
dobutamine treatment on any ScvO2-SvO2 discrepancy.
Materials and methods
Patients
The study protocol was approved by the National Ethics
Committee of Slovenia; informed consent was obtained
from all patients or their relatives. The study was per-
formed between October 2004 and June 2007.
After initial hemodynamic resuscitation according to
early goal-directed therapy [12] and Surviving Sepsis
Campaign guidelines [13], transthoracic echocardiogra-
phy for the assessment of left ventricular volume, ejec-
tion fraction (Simpson’s rule) and valvular function was
performed in all patients admitted to our ICU (Hewlett-
Packard HD 5000, Hewlett Packard, Andover, MA,
USA) by experienced ICU doctors (HM and MP) trained
in echocardiography.
In patients with primary heart disease, low cardiac
output, and no signs of hypovolemia, a right heart
catheterization with a pulmonary artery floating catheter
(Swan-Ganz CCOmboV CCO/SvO2/CEDV, Edwards
Lifesciences, Irvine, CA, USA) was performed following
a decision of the treating physician. The site of insertion
was confirmed by the transducer waveform, the length
of catheter insertion, and chest radiography. Systemic
arterial pressure was measured invasively using radial or
femoral arterial catheterization. Consecutive patients
with severe left heart failure due to primary heart dis-
ease (left ventricular systolic ejection fraction below
40%, pulmonary artery occlusion pressure above 18
mmHg) and additional severe sepsis/septic shock were
included in our study. Severe sepsis and septic shock
were defined according to the 1992 American College of
Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM) consensus conference definitions [14].
Patients with heart failure confirmed by echocardiogra-
phy without sepsis/septic shock were excluded. Patients
with cachexia were not included.
Patients were divided into two groups depending on
treatment with dobutamine or not.
All patients received standard treatment of localized
infection, severe sepsis and septic or cardiogenic shock
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infusion, organ failure replacement and/or support ther-
apy, intensive control of blood glucose and corticoster-
oid substitution therapy according to current Surviving
Sepsis Campaign Guidelines [13]. Mechanically venti-
lated patients were sedated with midazolam and/or pro-
pofol infusion. Paralytic agents were not used.
Measurements
Skeletal muscle oxygenation
Thenar muscle StO2 was measured non-invasively by
NIRS (25 mm Probe, InSpectra™, Hutchinson Technol-
ogy Inc., West Highland Park Drive NE, MN, USA)
[8,10,15]. Maximal thenar muscle StO2 was located by
moving the probe over the thenar prominence. StO2
was continuously monitored and stored onto a compu-
ter using InSpectra™ software. The average of StO2
changing over a 15 second span was used. The arterial
occlusion test was performed as previously reported
[10]: StO2 was monitored before and during (StO2 deox-
ygenation rate) upper limb ischemia until StO2
decreased to 40%. Upper limb ischemia was induced by
rapid automatic pneumatic cuff inflation (to
260 mmHg) placed above the elbow.
Severity of disease
Sepsis-related Organ Failure Assessment (SOFA) score
was calculated at the time of each measurement to
assess the level of organ dysfunction [16]. Dobutamine
and norepinephrine requirement represented the dose of
drug during the StO2 measurement. Use of an intra-
aortic balloon pump during the ICU stay is reported.
Plasma lactate concentration was measured using an
enzymatic colorimetric method (Lactate, Roche Diagnos-
tics, Hoffman-La Roche, Basel, Switzerland) at the time
of each StO2 measurement.
Laboratory analysis
Blood was withdrawn from the superior vena cava
approximately 2 cm above the right atrium and from
the pulmonary artery at the time of each StO2 measure-
ment to determine ScvO2 (%) and SvO2 (%), respec-
tively. In view of known problems arising during
sampling from the pulmonary artery, including the pos-
sibility of contaminating arterial blood with pulmonary
capillary blood, all samples from this site were with-
drawn over 30 seconds, using a low-negative pressure
technique, without inflating the balloon. A standard
volume of 1 mL of blood was obtained from each side
after withdrawal of dead-space blood and flushing fluid.
All measurements were made using a cooximeter (Rapi-
dLab 1265, Bayer HealthCare, Leverkusen, Germany).
Data analysis
A sample size of 41 patients was estimated for a correla-
tion coefficient of 0.6 with a desired power o f0.95 and
alpha of 0.01 (SigmaPlot 2004 for Windows, version
9.01 SyStat Software, Inc., Chicago, IL, USA).
Data was expressed as mean ± standard deviation
(SD). The Mann Whitney non-parametric test was used
to compare groups. A P value of less than 0.05 was con-
sidered statistically significant. The Pearson correlation
test was applied to determine correlation (SPSS 10.0 for
Windows™, SPSS Inc., Chicago, IL, USA). In order to
compare ScvO2 and SvO2 we calculated bias, systemic
disagreement between measurements (mean difference
between two measurements), precision and the random
error in measuring (SD of bias) [17]. The 95% limits of
agreement were arbitrarily set following Bland and Alt-
man as the bias ± two SD.
Results
During the study period (20 months), 2,121 patients
were admitted to the 15-bed university center internal
medicine ICU. In that period 151 right heart catheteri-
zations were performed. The final sample of 52 patients
was reached after exclusion of 65 patients with heart
failure without sepsis/septic shock, 24 patients who did
not have heart failure, 2 patients for whom consent was
not given and 8 patients for whom NIRS measurements
were not performed. The detailed description of our
selected population is given in Table 1. Patients were all
mechanically ventilated.
Intra-aortic balloon pumps were inserted in patients
who were treated with percutaneous coronary interven-
tion and stent implantation after primary cardiac arrest
due to ST-elevation myocardial infarction (STEMI; n =
42) and cardiogenic shock. Patients with STEMI after
cardiac arrest were treated with medically induced
hypothermia for 24 hours. During the ICU stay and
before study inclusion they all developed pneumonia.
All other patients were admitted to the ICU primarily
because of sepsis or septic shock.
Forty-three patients were treated with dobutamine.
There was no difference between patients treated with
or without dobutamine in additional hemodynamic sup-
port (Table 2). Patients treated with dobutamine had a
lower cardiac index (Table 3) and a higher procalcitonin
value (Table 4).
Thenar StO2 before (basal StO2) and during the vas-
cular occlusion test is presented in Table 5. There was
no difference between patients treated with and without
dobutamine in NIRS data.
SvO2 correlated significantly with ScvO2 (Pearson cor-
relation 0.659, P = 0.001; Figure 1); however, Bland Alt-
man analysis showed a clinically important difference
between both variables (ScvO2-SvO2 mean 72 ± 8%,
ScvO2-SvO2 difference 9.4 ± 7.5%; Figure 2).
The ScvO2-SvO2 difference correlated with plasma
lactate (Pearson correlation 0.400, P = 0.003; Figure 3)
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P = 0.001; Figure 4).
In the group of patients treated with dobutamine the
ScvO2-SvO2 difference correlated with plasma lactate
(Pearson correlation 0.389, P = 0.011) and StO2 deoxy-
genation rate (Pearson correlation 0.777, P = 0.0001).
In a small group of patients (n = 9) treated without
dobutamine the ScvO2-SvO2 difference correlated with
the StO2 deoxygenation rate (Pearson correlation 0.673,
P = 0.033); however, there was no correlation between
the ScvO2-SvO2 difference and plasma lactate (Pearson
correlation 0.503, P = 0.139).
Discussion
Our study confirmed the hypothesis that the skeletal
muscle StO2 deoxygenation rate correlates (or is
inversely proportional) to the ScvO2-SvO2 difference in
patients with severe heart failure with additional sepsis/
septic shock. This relation between the StO2 deoxygena-
tion rate and the ScvO2-SvO2 difference was also pre-
sent in patients treated with or without dobutamine. We
also showed that these patients have a clinically consid-
erable ScvO2-SvO2 discrepancy. Monitoring of ScvO2 is
a simpler and cheaper assessment of global DO2 to oxy-
gen consumption ratio, but its use as a treatment goal
in patients with severe heart failure with additional sep-
sis/septic shock is questionable.
The high StO2/low SvO2 seen in patients with severe
sepsis and septic shock suggests blood flow redistribu-
tion. Thenar muscle StO2 correlates with central venous
oxygen saturation that is measured in a mixture of
blood from the head and both arms [18]. In healthy
Table 1 Description of patients
Parameter All
(n = 52)
Treatment
with dobutemine
(n = 43)
Treatment
without dobutamine
(n = 9)
P value
Age (years) 68 ± 13 68 ± 14 69 ± 8 0.8
Female (n) 7 5 2 0.6
Heart disease
Ischemic heart disease (n) 42 36 6 0.4
Aortic stenosis (n) 6 4 2 0.6
Dilated cardiomyopathy (n) 1 1 0 0.9
Myocarditis (n) 3 2 1 0.6
Echocardiography
LVEF (%) 28 ± 5 25 ± 8 29 ± 9 0.1
LVEDD (cm) 5.8 ± 0.9 5.8 ± 0.7 6.0 ± 0.9 0.2
Severe mitral regurgitation (n) 26 22 4 0.8
Cause of infection
Pneumonia (n) 45 38 7 0.6
Urosepsis (n) 5 4 1 0.9
Other (n) 2 1 1 0.7
SOFA score 12.2 ± 2.5 12. ± 2.2 12.6 ± 2.6 0.8
ICU stay (days) 9 ± 4 9 ± 6 9 ± 5 0.9
ICU survival (%) 48 47 55 0.8
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; SOFA, Sequential Organ Failure Assessment.
Table 2 Treatment of patients
Treatment All
(n = 52)
Treatment
with dobutemine
(n = 43)
Treatment
without dobutamine
(n = 9)
P value
Norepinephrine (mg/h, n) 0.09 ± 0.10 (43) 0.08 ± 0.11
(37)
0.04 ± 0.06
(9)
0.1
Dobutamine (μg/kg/min) - 0.47 ± 0.25 - -
Levosimendan (n) 23 17 6 0.2
IAPB (n) 20 15 5 0.3
Mechanical ventilation(n) 52 43 9 1.0
FiO2 0.72 ± 0.22 0.73 ± 0.23 0.71 ± 0.23 0.8
FiO2, fractional inspired oxygen; IAPB, intra-aortic balloon pump.
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SvO2 [3]. Blood in the inferior vena cava has a high oxy-
gen content because the kidneys do not utilise much
oxygen but receive a high proportion of the cardiac out-
put [19]. Blood in the inferior vena cava blood has a
higher oxygen content than blood from the upper body
and the SvO2 is thus greater than the ScvO2.
This relation changes in periods of cardiovascular
instability. Scheinman and colleagues performed the ear-
liest comparison of ScvO2 and SvO2 in both hemodyna-
mically stable and shockedp a t i e n t s[ 5 ] .I ns t a b l e
patients, ScvO2 was similar to SvO2. In patients with a
failing heart, ScvO2 was slightly higher than SvO2 and in
patients with shock the difference between SvO2 and
ScvO2 was even more expressed (47.5% ± 15.11% vs.
58.0% ± 13.05%, respectively, P < 0.001). Lee and collea-
gues described similar findings [20]. Other more
detailed studies in mixed groups of critically ill patients
designed to test if the ScvO2 measurements could sub-
stitute the SvO2 showed problematically large confi-
dence limits [6] and poor correlation between the two
values [7].
Table 3 Hemodynamic data in patients with heart failure and additional sepsis treated with and without dobutamine
Hemodynamic data All
(n = 52)
Treatment
with dobutemine
(n = 43)
Treatment
without dobutamine
(n = 9)
P value
HR (bpm) 113 ± 20 113 ± 20 114 ± 21 0.8
SAP (mmHg) 118 ± 21 117 ± 20 124 ± 27 0.9
DAP (mmHg) 74 ± 22 76 ± 22 66 ± 21 0.4
PAPs (mmHg) 57 ± 14 56 ± 13 57 ± 16 0.9
PAPd (mmHg) 28 ± 8 27 ± 8 29 ± 7 0.4
CVP (mmHg) 16 ± 5 16 ± 5 15 ± 5 0.8
DO2 (ml/kg/min) 406 ± 128 391 ± 134 470 ± 121 0.1
VO2 (ml/kg/min) 118 ± 42 116 ± 43 126 ± 38 0.5
PAOP (mmHg) 23 ± 7 24 ± 7 22 ± 8 0.7
CI (L/min/m
2) 2.5 ± 0.7 2.4 ± 0.7 2.9 ± 0.6 0.03
SvO2 (%) 67 ± 10% 66 ± 10 71 ± 7 0.2
ScvO2 (%) 77 ± 8% 77 ± 7 78 ± 10 0.6
Bold: statistically significant difference, P < 0.05.
CI, cardiac index; CVP, central venous pressure; DAP, diastolic arterial pressure; DO2, delivery of oxygen; HR, heart rate; PAOP, pulmonary artery occlusion
pressure; PAPd, diastolic pulmonary arterial pressure; PAPs, systolic pulmonary arterial pressure; SAP, systolic arterial pressure; SvO2, mixed venous hemoglobin
saturation; ScvO2, central venous oxygen saturation; VO2, oxygen consumption.
Table 4 Laboratory data
Laboratory data All
(n = 52)
Treatment
with dobutemine
(n = 43)
Treatment
without dobutamine
(n = 9)
P value
Core temperature (°C) 38.0 ± 0.9 37.9 ± 0.87 38.2 ± 0.92 0.5
Lactate (mmol/l) 3.5 ± 3.0 3.6 ± 3.3 3.0 ± 1.7 0.4
CRP (mg/l) 127 ± 78 124 ± 65 154 ± 120 0.6
PCT (mg/l) 6.2 ± 6.1 7.2 ± 6.3 2.5 ± 4.2 0.01
Leucocytes (*10
9/l) 14.0 ± 5.4 13.8 ± 5.3 15.4 ± 6.3 0.5
Hemoglobin (g/L) 11.6 ± 1.5 11.6 ± 1.6 11.6 ± 1.0 0.9
Creatinine 198 ± 160 162 ± 142 231 ± 182 0.1
Sodium (mmol/L) 144 ± 12 144 ± 11 147 ± 14 0.8
Arterial blood gal analysis
pH 7.35 ± 0.09 7.35 ± 0.08 7.33 ± 0.09 0.6
pCO2 (kPa) 4.7 ± 1.0 4.6 ± 1.0 5.3 ± 0.8 0.06
pO2 (kPa) 15.3 ± 5.4 14.6 ± 4.8 18.5 ± 7.4 0.1
HCO3 (mmol/L) 20.6 ± 5.6 20.4 ± 6.1 21.5 ± 3.9 0.5
BE(mEq/l) -5.1 ± 6.4 -5.4 ± 6.9 -4.2 ± 4.8 0.5
SatHbO2 (%) 97 ± 3% 97 ± 2 98 ± 3 0.4
Bold: statistically significant difference, P < 0.05.
BE, base excess; CRP, C-reactive protein; HCO3, bicarbonate; PCT, procalcitonin; pCO2, partial pressure of carbon dioxide; pO2, partial pressure of oxygen; SatHbO2,
hemoglobin oxygen saturation.
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tribution of cardiac output that occur in periods of hemo-
dynamic instability. In shock states, blood flow to the
splanchnic and renal circulations falls, while flow to the
heart and brain is maintained [21]. This results in a fall in
the oxygen content of blood in the inferior vena cava. As a
consequence, in shock states the normal relation is
reversed and ScvO2 is greater than SvO2 [5]. Therefore,
when using ScvO2 or StO2 as a treatment goal, the relative
oxygen consumption of the superior vena cava system
may remain stable, while the oxidative metabolism of vital
organs, such as the splanchnic region, may reach a level
where a flow-limited oxygen consumption is achieved,
together with a marked decrease in oxygen saturation. In
this situation skeletal muscle StO2 provides a false favor-
able impression of an adequate body perfusion, because of
the inability to detect organ ischemia in the lower part of
the body.
In our study, three patients with septic shock had ske-
letal muscle StO2 of 75% or less (under the lower
boundary of 95% confidence interval for the mean of
StO2 in controls); they were all in septic shock (lactate
value above 2.5 mmol/L) with a low cardiac index below
2.0 L/min/m
2. These patients were probably in an early
under-resuscitated phase of septic shock. The low quan-
tity of septic patients with low StO2 did not allow statis-
tical comparison of StO2 and SvO2/SvO2 in these types
of patients. Additional research is necessary to study
muscle skeletal StO2 in under resuscitated septic
patients.
O u rd a t aa r es u p p o r t e db yp r e v i o u sw o r kb yB o e k s t e -
gers and colleagues who measured the oxygen partial
Table 5 NIRS data of skeletal muscle tissue oxygenation (StO2) during vascular occlusion test in patients with heart
failure and additional sepsis
NIRS data All
(n = 52)
Treatment
with dobutemine
(n = 43)
Treatment
without dobutamine
(n = 9)
P value
Basal StO2 (%) 89 ± 8 88 ± 8 92 ± 6 0.1
StO2 deoxygenation
rate (%/min)
-12.6 ± 4.9 -12.7 ± 5.2 -12.6 ± 4.6 0.9
NIRS, near-infrared spectroscopy; StO2, skeletal muscle tissue oxygenation.
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Figure 1 Correlation between mixed venous (SvO2) and central venous saturation (ScvO2) in patients with heart failure and additional
sepsis/septic shock. Pearson correlation 0.659, P = 0.001.
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Figure 2 Bland Altman analysis of clinically important difference between mixed venous (SvO2) and central venous saturation (ScvO2)
in patients with heart failure and additional sepsis/septic shock. ScvO2-SvO2 mean 72 ± 8%, Scv-Svo2 difference 9.4 ± 7.5%.
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Figure 3 Correlation of mixed venous (SvO2) and central venous saturation (ScvO2) difference with plasma lactate (mmol/L).P e a r s o n
correlation 0.400, P = 0.003.
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low peripheral oxygen availability in cardiogenic shock
compared with sepsis. In cardiogenic shock the skeletal
muscle oxygen partial pressure correlated with systemic
oxygen delivery (r = 0.59, P < 0.001) and systemic vas-
cular resistance (r = 0.74, P < 0.001). No correlation was
found between systemic oxygen transport variables and
the skeletal muscle partial oxygen pressure in septic
patients. These measurements were performed in the
most common cardiovascular state of sepsis in contrast
to hypodynamic shock, which is only present in the very
final stage of sepsis or in patients without adequate
volume replacement [23]. In a following study the same
authors have shown that even in the final state of hypo-
dynamic septic shock leading to death, the mean muscle
partial oxygen pressure did not decrease to below
4.0 kPa before circulatory standstill [24].
A recent study confirmed the use of NIRS and the
arterial occlusion test in the assessment of peripheral
muscle microcirculation impairment in patients with
congestive heart failure [11]. This impairment of micro-
circulation was partially reversed by infusion of the ino-
tropic agent dobutamine but not by levosimendan. In
chronic heart failure patients, dobutamine increases car-
diac output and improves tissue perfusion, which leads
to improvement of endothelial function and tissue oxy-
genation. It was demonstrated that short-term
(72 hours) and short-term intermittent (for five hours,
biweekly) administration of dobutamine has a sustained
beneficial effect on vascular endothelial function for two
weeks or longer and after four months, respectively
[25,26]. Despite this effect of dobutamine on endothelial
function in patients with chronic heart failure, we have
not detected any difference in StO2 deoxygenation in
our mixed population of patients with left heart failure
and additional sepsis/septic shock treated with or with-
out dobutamine. Sepsis/septic shock-related microvascu-
lar changes and the lack of inclusion of end-stage heart
failure patients in our study are probably causes for dis-
crepancy between the results of our study and the study
performed by Nanas and colleagues [11].
It is known that progressive chronic heart failure leads
to cardiac cachexia and decreased resting energy expen-
diture, both of which are worst outcome predictors [27].
Previously, we have shown that in these patients meta-
bolism is changed to the predominant utilization of
lipids [28]. However, these changes happen in stages of
advanced chronic heart failure, while on the other hand
in patients without cachexia the resting energy expendi-
ture is increased proportionally to a higher New York
Heart Association class [29]. No patients with cardiac
cachexia were included in our study. The effects of
dobutamine on skeletal muscle metabolism in patients
with chronic heart failure were studied by magnetic
resonance spectroscopy, which indicated that dobuta-
mine has the ability to increase cardiac output and limb
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Figure 4 Correlation of central venous saturation (ScvO2) central venous saturation (SvO2) difference with skeletal muscle tissue
oxygenation (StO2) deceleration rate. Pearson correlation 0.651, P = 0.001.
Možina and Podbregar Critical Care 2010, 14:R42
http://ccforum.com/content/14/2/R42
Page 8 of 10blood flow, although it does not improve oxygen deliv-
ery to the working muscle of the patients [30]. Increased
resting blood flow can result in increased oxyhemoglo-
bin content in muscle leading to increased basal StO2
but the StO2 deoxygenation rate should stay unchanged
if the metabolic rate remains constant.
Conclusions
In patients with severe heart failure with additional sep-
sis/septic shock, there is a clinically important discre-
pancy between ScvO2 and SvO2. However, with the use
of arterial occlusion testing and measurement of the
skeletal muscle deoxygenation rate, we can predict the
ScvO2-SvO2 difference and determine adequate moni-
toring. Dobutamine use did not change this relation.
Applying these findings in practice, in a patient with
severe left heart failure, first perform arterial occlusion
testing to determine the StO2 deoxygenation rate. If it is
high (not prolonged as seen in sepsis/septic shock), esti-
mate the SvO2 by using basal StO2. In the case of a pro-
longed skeletal muscle StO2 deoxygenation rate, look for
additional sepsis, and the deoxygenation rate can esti-
mate discrepancy between the ScvO2 and SvO2.
Key messages
￿ In patients with severe left heart failure and addi-
tional severe sepsis or septic shock the ScvO2-SvO2
discrepancy is clinically important.
￿ The skeletal muscle StO2 deoxygenation rate esti-
mates the ScvO2-SvO2 discrepancy in patients with
severe left heart failure with additional severe sepsis
or septic shock.
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